Compare ResMed Inc. (RMD) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Tripadvisor Inc Common Stock — how do they compare? ResMed Inc. trades at $223.62 (market cap $31.92B), while Tripadvisor Inc Common Stock trades at $11.04 (market cap $1.26B). The key difference: ResMed Inc. is far larger — about 25.3× Tripadvisor Inc Common Stock's market cap, and ResMed Inc. pays a 1.2% dividend while Tripadvisor Inc Common Stock pays none. Which is the better fit depends on your goals.
| RMD | TRIP | |
|---|---|---|
Market Cap | $31.92B | $1.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $293.73 | $19.14 |
52-Week Low | $182.82 | $9.24 |
Enterprise Value | $31.28B | $1.31B |
Dividend Yield | 1.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $211.94, down 5.06% on the day, following a Q4 2026 earnings beat but weaker fiscal 2027 revenue guidance. The stock shows strong fundamentals with a 26.94% net income margin and consistent earnings beats, while technical indicators are neutral with support at $204 and resistance at $218. Recent news highlights growth in sleep device demand but concerns over sales forecasts.
Outlook remains mixed: robust profitability and a $235 consensus price target suggest upside, but near-term pressure from guidance and technical neutrality poses risks. Investors should weigh solid financial health against market sentiment shifts.
Tripadvisor (TRIP) trades at $10.78, up 3.45% today, but faces bearish technical signals with recent earnings misses. The company maintains strong gross margins at 92.11% but struggles with thin net income margins of 0.27%. Recent Q2 2026 results missed expectations, though the $700M sale of TheFork to American Express provides strategic focus and cash infusion. Analyst consensus is mixed with 62.5% hold ratings and a $13.71 price target suggesting 27% upside potential from current levels.
TRIP presents a turnaround opportunity with simplified operations post-TheFork sale and Viator's growth potential, but faces persistent search-related pressures and uneven travel demand. The stock trades at reasonable valuations (P/S 0.7x) but carries execution risks amid competitive threats. Cash flow trends show volatility, with negative net cash flow projected for 2026, requiring careful monitoring of the company's strategic execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
